Last reviewed · How we verify
Progesterone Only Hormone Replacement Therapy
At a glance
| Generic name | Progesterone Only Hormone Replacement Therapy |
|---|---|
| Also known as | Progesterone only |
| Sponsor | New Mexico Cancer Research Alliance |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Postplacental Copper Intrauterine Device Versus Postpartum Progesterone-only Pills on Uterine Niche Formation (NA)
- Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial (PHASE2)
- Impact of Different Doses and Routes of Exogenous Progesterone Administration on Endometrial Receptivity Parameters (PHASE4)
- Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency
- The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin D in Preventing Preterm Birth: (NA)
- Cerclage With Progesterone Versus Progesterone Only in Singleton Pregnancies (NA)
- Nintedanib for Improving Reproductive Outcomes in Adenomyosis (PHASE3)
- Menopausal HT for Women Living With HIV (HoT) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: